Meeting
2018 ASCO Annual Meeting
DLBCL outcomes in Malawi: Effect of HIV and derivation of a simplified prognostic score.
Authors
Matthew Painschab
Lineberger Comprehensive Cancer Center; University of North Carolina, Chapel Hill, NC
Matthew Painschab , Edwards Kasonkanji , Takondwa Zuze , Bongani Kaimila , Tamiwe Tomoka , Bal Dhungel , Maurice Mulenga , Maria Chikasema , Blessings Tewete , Asekanadziwa Mtangwanika , Sarah Chiyoyola , Wilberforce Mhango , Fred Chimzimu , Coxcilly Kampani , Robert Krysiak , Thomas C. Shea , Nathan Montgomery , Yuri Fedoriw , Satish Gopal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7565)
DOI
10.1200/JCO.2018.36.15_suppl.7565
Abstract #
7565
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.
First Author: Adam J. Olszewski
Poster
2016 ASCO Quality Care Symposium
Diffuse large B-cell lymphoma: A single-institution experience of patient outcomes.
First Author: Ryan James Chan
Poster
2011 ASCO Annual Meeting
Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
First Author: J. D. Hainsworth
Poster
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
First Author: Hua-Jay Jeffery Cherng